SENSORION SA (ALSEN.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALSEN - FR0012596468 - Common Stock
ALSEN.PA Key Statistics, Chart & Performance
The current stock price of ALSEN.PA is 0.326 EUR. In the past month the price increased by 3.82%. In the past year, price decreased by -52.48%.
ALSEN.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 65.13 | 42.70B | ||
| 1AE.DE | ARGENX SE | 65.22 | 42.77B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.72B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.71B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.64B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 856.31M | ||
| IVA.PA | INVENTIVA SA | N/A | 782.22M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About ALSEN.PA
Company Profile
Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 68 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
Company Info
SENSORION SA
375, rue du Professeur Joseph Blayac
Montpellier OCCITANIE FR
Employees: 63
Phone: 33467207730
SENSORION SA / ALSEN.PA FAQ
What does SENSORION SA do?
Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 68 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
Can you provide the latest stock price for SENSORION SA?
The current stock price of ALSEN.PA is 0.326 EUR. The price increased by 5.5% in the last trading session.
What is the dividend status of SENSORION SA?
ALSEN.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALSEN stock?
ALSEN.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of ALSEN stock?
SENSORION SA (ALSEN.PA) has a market capitalization of 98.02M EUR. This makes ALSEN.PA a Micro Cap stock.
When does SENSORION SA (ALSEN.PA) report earnings?
SENSORION SA (ALSEN.PA) will report earnings on 2026-03-12, after the market close.
ALSEN.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALSEN.PA. When comparing the yearly performance of all stocks, ALSEN.PA is a bad performer in the overall market: 95.23% of all stocks are doing better.
ALSEN.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALSEN.PA. While ALSEN.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALSEN.PA Financial Highlights
Over the last trailing twelve months ALSEN.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 10% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.36% | ||
| ROE | -49.12% | ||
| Debt/Equity | 0.01 |
ALSEN.PA Forecast & Estimates
13 analysts have analysed ALSEN.PA and the average price target is 2.42 EUR. This implies a price increase of 643.1% is expected in the next year compared to the current price of 0.326.
For the next year, analysts expect an EPS growth of 13.89% and a revenue growth 0.07% for ALSEN.PA